|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9426
|
|
pubmed:dateCreated |
2004-6-21
|
|
pubmed:abstractText |
Rheumatoid arthritis is characterised by inflammatory synovitis, articular destruction, and accelerated atherogenesis. HMG-CoA (3-hydroxy-3-methylglutarylcoenzyme A) reductase inhibitors (statins) mediate clinically significant vascular risk reduction in patients without inflammatory disease and might have immunomodulatory function. We postulated that statins might reduce inflammatory factors in rheumatoid arthritis and modify surrogates for vascular risk.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/Heptanoic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/atorvastatin,
http://linkedlifedata.com/resource/pubmed/chemical/von Willebrand Factor
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
19
|
|
pubmed:volume |
363
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2015-21
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15207950-Aged,
pubmed-meshheading:15207950-Antirheumatic Agents,
pubmed-meshheading:15207950-Arthritis, Rheumatoid,
pubmed-meshheading:15207950-Biological Markers,
pubmed-meshheading:15207950-Blood Sedimentation,
pubmed-meshheading:15207950-Blood Viscosity,
pubmed-meshheading:15207950-C-Reactive Protein,
pubmed-meshheading:15207950-Cardiovascular Diseases,
pubmed-meshheading:15207950-Double-Blind Method,
pubmed-meshheading:15207950-Drug Therapy, Combination,
pubmed-meshheading:15207950-Female,
pubmed-meshheading:15207950-Glucocorticoids,
pubmed-meshheading:15207950-Heptanoic Acids,
pubmed-meshheading:15207950-Humans,
pubmed-meshheading:15207950-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:15207950-Lipids,
pubmed-meshheading:15207950-Male,
pubmed-meshheading:15207950-Methotrexate,
pubmed-meshheading:15207950-Middle Aged,
pubmed-meshheading:15207950-Pyrroles,
pubmed-meshheading:15207950-Risk Factors,
pubmed-meshheading:15207950-von Willebrand Factor
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
|
|
pubmed:affiliation |
Centre for Rheumatic Diseases, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
